viewGlaxoSmithKline PLC

GlaxoSmithKline, Sanofi start early-stage trial for coronavirus vaccine

The final trial is planned to start in December if data from the current one can support it

GlaxoSmithKline PLC - GlaxoSmithKline, Sanofi start early-stage trial for COVID-19 vaccine

GlaxoSmithKline PLC (LON:GSK) has announced the start of Phase 1/2 clinical trial for the coronavirus (COVID-19) vaccine it has developed with France's Sanofi.

The trial, which aims at evaluating the safety, tolerability and immune response, will be conducted on 440 healthy adults across 11 investigational sites in the US.

READ: The runners in the COVID-19 vaccine race

Results are expected in December, with the pair looking to start the final phase of trials in the same month.

If data is enough to apply for approval, it will be requested in the first half of 2021.

The candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines with GSK's established pandemic adjuvant technology.

Meanwhile, both drugs giants are scaling up manufacturing to reach 1bn doses next year.

Pre-clinical data collected by Sanofi showed acceptable tolerability, with results to be published later this year.

Shares advanced 1% to 1,498.4p on Thursday at the opening bell.

--Adds shares--

Quick facts: GlaxoSmithKline PLC

Price: 1525.6 GBX

Market: LSE
Market Cap: £76.54 billion


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Market report: FTSE fragile Friday despite UK shoppers continuing to splurge...

Good morning, it’s a fragile Friday for the FTSE despite signs of some retail therapy as British retail sales continued to increase for the fourth consecutive month, boosted by spending on household goods and DIY, according to the ONS.  J Sainsbury PLC (LON:SBRY) is up after a...

2 days, 4 hours ago

2 min read